Clinical trial · Observational
Real-life Data of Olaparib in Relapsed Ovarian Cancers Patients
Observational Retrospective Cohort Study in Patients With Relapsed Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Treated With Olaparib Following Response to Platinium-based Chemotherapy
NCT04152941CI-TRIAL-00069340RETROLAcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a national, multi center, retrospective observational cohort study that will be carried out by reviewing the medical records of patients with relapsed epithelial ovarian, fallopian tube, or peritoneal cancer treated with olaparib following response to platinum-based chemotherapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Relapsed Ovarian Cancers Patients | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Olaparib | Drug | Olaparib | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (3)
- measure
- progression free survival (PFS)
- timeFrame
- through study completion, an average of 1 year
- description
- PFS (days) = date of progression - date of treatment start + 1
- measure
- overall Survival (OS)
- timeFrame
- through study completion, an average of 1 year
- description
- OS (days) = date of death - date of treatment start + 1
- measure
- incidence of events of clinical interest
- timeFrame
- through study completion, an average of 1 year
- description
- the following events: anemia, thrombopenia, nausea and vomiting, fatigue, myelodysplastic syndrome, upper respiratory infections, diarrhea, decreased appetite, dysgeusia and headache will be formally retrieved from the source documents.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients must be female ≥18 years of age * Patients with histologically confirmed ovarian cancer, primary peritoneal cancer and / or fallopian-tube cancer that were treated with olaparib in a real life-setting, between May 2014 to March 2017, whatever the line of therapy * Patients can be either alive or deceased at the time of medical record abstraction * Patients should not have any objection that anonymized data will be collected and subjected to automated processing. Exclusion Criteria: * Patient that were given olaparib within a clinical trial
References
Publications (0)
Data not yet available
No reference posted for this study.